skip to Global Navigation Bar skip to main content


homeHome > About Us > Press Release > News

News

News Content
Daewoong’s ‘NABOTA’ submitted the form to change clinical test plans in China.
Date 2019-01-07 Hit 2273
list
News List
Prev DAEWOONG Pharmaceutical’s New Year’s greetings: “The year 2019 will be the first year of our challenge to be a global healthcare group”
Next The clinical findings of Botulinum Toxin manufactured by Daewoong have been published on international journal regarding the comparison with Botox